Understanding disease-related molecular mechanisms and profiles in lung adenocarcinoma affected differently depending on the type of EGFR gatekeeper mutation would be greatly useful in deciding treatment strategies that benefit the outcomes of individual patients. The gene discussed is EGFR; the disease is lung adenocarcinoma.